A Comparison of the Control of Asthma Provided by Symbicort® Turbuhaler® Versus Symbicort® Turbuhaler® Plus Pulmicort® Turbuhaler® Plus Terbutaline Turbuhaler®

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: Terbutaline Turbuhaler; Drug: Budesonide/Formoterol Turbuhaler; Drug: Budesonide Turbuhaler (Pulmicort)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00244608

D5890C00003

EudraCT no. 2004-004042-41

Details and patient eligibility

About

The purpose of this study is to determine if a flexible dose of Symbicort has a similar effect on the airways of patients with asthma as a higher fixed-dose of Symbicort with additional glucocorticosteroids added.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of asthma for at least 6 months
• Prescribed daily use of glucocorticosteroids for at least 3 months prior to visit one

Exclusion criteria

• Respiratory infection affecting asthma within 30 days prior to study
• Intake of oral, rectal, or parenteral glucocorticosteroids within 30 days prior to study
• Any significant disease or disorder that may jeopardize the safety of the patient

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind